An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

Af­ter flop­ping a test in Covid-19 ear­li­er this year, An­gion’s lead or­gan dam­age drug has now hit the skids again in kid­ney trans­plant pa­tients. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.